Triplet Regimen, Biomarker Gate, Phase 3 Signal: What ILUSTRO’s Cohort 4 Actually Proves
Astellas's ILUSTRO trial just published Phase 2 data showing a zolbetuximab-nivolumab-mFOLFOX6 triplet in CLDN18.2-positive gastric cancer produces response rates...